Built to help voters verify how officials vote using official public records — non-partisan, no spin, no jargon.
H.R. 919 · 119th Congress

Chronic Disease Flexible Coverage Act

In committee

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Bill details

Introduced: 2/4/2025
Current status: In committee
Bill ID: 119hr919
Latest official action: Received in the Senate and Read twice and referred to the Committee on Finance.

Bill overview

A neutral overview based on official congressional sources.

Introduced in House

Chronic Disease Flexible Coverage Act This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold. Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include • angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease; • anti-resorptive therapy for individuals with osteoporosis or osteopenia; • beta-blockers for individuals with congestive heart failure or coronary artery disease; • blood pressure monitors for individuals with hypertension; • inhaled corticosteroids and peak flow meters for individuals with asthma; • insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes; • international normalized ratio testing for individuals with liver disease or bleeding disorders; • low-density lipoprotein testing for individuals with heart disease; • statins for individuals with heart disease or diabetes; and • selective serotonin reuptake inhibitors for individuals with depression. The bill provides statutory authority for the IRS's guidance.

Source: BILLSUM · Summary date: 2/4/2025

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. No interpretation.

About this data

Non-partisan by design
OurCongress presents public records without political endorsement, interpretation, or advocacy.
Official sources
Data is sourced from official government records, including Congress.gov, GovInfo, the Clerk of the House, and the U.S. Senate.
AI-generated text
Some explanatory sections may be generated from official summaries and metadata to improve readability. They are not official government language and should be verified against primary sources.
Last updated: 2/4/2025Source: BILLSUMBill: 119hr919Learn more →